Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1.]
R.I. Fox.
Sjögren's syndrome.
Lancet, (2005), 366 pp. 321-331
[2.]
H. Sjogren.
Auf kenntnis der kertoconjunctivitis sicca (keratitisfiliformis bei hypofunction der transendrusen).
Acta Ophthalmol (Kbh), (1933), 11 pp. 1-15
[3.]
R.I. Fox, M. Stern, P. Michelson.
Update in Sjogren's syndrome.
Curr Opin Rheumatol, (2000), 12 pp. 391-398
[4.]
U.G. Dafni, A.G. Tzioufas, P. Staikos, F.N. Skopouli, H.M. Moutsopoulos.
Prevalence of Sjögren's syndrome in a clased rural community.
Ann Rheum Dis, (1997), 56 pp. 521-525
[5.]
E. Thomas, E.M. Hay, A. Hajeer, A.J. Silman.
Sjögren's syndrome: a community-based study of prevalence and impact.
Br J Rheumatol, (1998), 37 pp. 1069-1076
[6.]
A.P. Andonopoulos, A.A. Drosos, F.N. Skopouli, N.C. Acritidis, H.M. Moutsopoulos.
Secondary Sjögren's syndrome in rheumatoid arthritis.
J Rheumatol, (1987), 1 pp. 1098-1103
[7.]
H.M. Moutsopoulos, B.L. Webber, T.P. Viagopoulos, T.M. Chused, J.L. Decker.
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis.
Am J Med, (1979), 66 pp. 733-736
[8.]
M. G García-Carrasco, M. Ramos-Casals, J. Rosas, L. Pallarés, J. Calvo-Alen, R. Cervera, et al.
Primary Sjögren's syndrome: clinical and immunologic disease patterns in a cohorte of 400 patients.
Medicine (Baltimore), (2002), 81 pp. 270-280
[9.]
A. Triantafyllopoulou, H.M. Moutsopoulos.
Autoimmunity and Coxsackie-virus infection in primary Sjögren's syndrome.
Ann N Y Acad Sci, (2005), 1050 pp. 389-396
[10.]
A. Hansen, P.E. Lipsky, T. Dorner.
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
Curr Opin Rheumatol, (2005), 17 pp. 558-565
[11.]
A. Hansen, K. Reiter, T. Ziprian, A. Jacobi, A. Hoffmann, M. Gosemann, et al.
Dysregulation of chemokine receptor expresion and function by B cells of patients with primary Sjögren's syndrome.
Arthritis Rheum, (2005), 52 pp. 2109-2119
[12.]
M. Ramos-Casals, J. Font.
Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts.
Rheumatology (Oxford), (2005), 44 pp. 1354-1367
[13.]
S.S. Kassan, H.M. Moutsopoulos.
Clinical manifestations and early diagnosis of Sjögren's syndrome.
Arch Intern Med, (2004), 164 pp. 1275-1284
[14.]
J. Font, M. Ramos-Casals, G. de la Red, A. Pou, A. Casanova, M. García-Carrasco, et al.
Pure sensory neurophaty in primary Sjögren's syndrome. Longterm prospective followup and review of the literature.
J Rheumatol, (2003), 30 pp. 1552-1557
[15.]
P. Brito-Zerón, M. Ramos-Casals, A. Bove, J. Sentis, J. Font.
Predicting adverse outcomes in primary Sjögren's syndrome: inditification of prognostic factors.
Rheumatology (Oxford), (2007), 46 pp. 1359-1362
[16.]
C. Vitali, S. Bombardieri, R. Jonsson, H.M. Moutsopoulos, E.L. Alexander, S.E. Carsons, et al.
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.
Ann Rheum Dis, (2002), 61 pp. 554-558
[17.]
P. Morbini, A. Manzo, R. Caporali, O. Epis, C. Villa, C. Tinelli, et al.
Multilevel examination of minor salivary gland biopsy for Sjögren's syndrome significantly improves diagnostic performance of AECG classification criteria.
Arthritis Res Ther, (2005), 7 pp. R343-R348
[18.]
N.M. Moutsopoulos, H.M. Moutsopoulos.
Therapy of Sjögren's syndrome.
Springer Semin Immunopathol, (2001), 23 pp. 131-145
[19.]
J. Rosas, M. García-Carrasco, M. Ramos-Casals, A. Bermejo, et al.
Tratamiento de la afectación oral.
Síndrome de Sjögren, Ed. Masson, pp. 531-538
[20.]
C.P. Mavragani, N.M. Moutsopoulos, H.M. Moutsopoulos.
The management of Sjögren's syndrome.
Nat Clin Pract Rhematol, (2006), 2 pp. 252-261
[21.]
P. Brito-Zerón, M. Ramos-Casals, N. Nardi, J. Font.
Results of the treatment with oral pilocarpine in 100 patients with primary Sjögren's syndrome.
Med Clin (Barc), (2006), 126 pp. 637
[22.]
P.C. Fox, P.F. Van der Ven, B.J. Baum, I.D. Mandel.
Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction.
Oral Surg Oral Med Oral Pathol, (1986), 61 pp. 243-248
[23.]
N. Tsifetaki, G. Kitsos, C.A. Paschides, Y. Alamanos, V. Eftaxias, P.V. Voulgari.
Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.
Ann Rheum Dis, (2003), 62 pp. 1204-1207
[24.]
R. Solans, J.A. Bosch, A. Selva, C.P. Simeon, V. Fonollosa, M. Vilardell.
Pilocarpina oral en el tratamiento de la xerostomía y xeroftalmía en pacientes con síndrome de Sjögren primario.
Med Clin (Barc), (2004), 122 pp. 253-255
[25.]
R.S. Fife, W.F. Chase, R.K. Dore, C.W. Wiesenhutter, P.B. Lockhart, E. Tindall, et al.
Cevimeline for the treatment of xerostomia in patients with Sjögren's syndrome.
Arch Intern Med, (2002), 162 pp. 1293-1300
[26.]
J.M. Vázquez, M. Grau, P. Díaz, J.R. Fontenla, et al.
Tratamiento de la afectación ocular.
Síndrome de Sjögren, Ed. Masson, pp. 539-550
[27.]
M. Ramos-Casals, A.G. Tzioufas, J. Font.
Sjögren's syndrome. New therapeutic approaches.
Med Clin (Barc), (2005), 124 pp. 111-115
[28.]
V. Devauchelle-Pensec, Y. Pennec, J. Morvan, J.O. Pers, C. Daridson, S. Juosse-Joulin.
Improvement after two infusion of Sjögren's syndromeions of rituximab (anti-CD20).
Arthritis Rheum, (2007), 57 pp. 310-317
[29.]
J. Pijpe, G.W. Van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, K. Mansour.
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Arthritis Rheum, (2005), 52 pp. 2740-2750
[30.]
T. Ring, M. Kallenbach, J. Praetorius, S. Nielsen, B Melgaard.
Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
Clin Rheumatol, (2006), 25 pp. 891-894
[31.]
Z. Touma, J. Sayad, T. Arayssi.
Successful treatment of Sjögren's syndrome with Rituximab.
Scand J Rhematol, (2006), 35 pp. 323-325
[32.]
M. Ramos-Casals, P. Brito-Zerón.
Emerging biological therapies in primary Sjögren's syndrome.
Rheumatology (Oxford), (2007), 46 pp. 1389-1396
[33.]
S.D. Steinfeld, L. Tant, G.R. Burmester, N.K. Teoh, W.A. Wegener, D.M. Goldenberg, et al.
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Arthritis Res Ther, (2006), 8 pp. 129
[34.]
W.G. Halpern, P. Lappin, T. Zanardi, W. Cai, M. Corcoran, J. Zhong, et al.
Chronic administration of Belimumab, a BLys antagonist, decrease tissues and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
Toxicol Sci, (2006), 91 pp. 586-599
Copyright ©
2009. Elsevier España, S.L.. Todos los derechos reservados
